Financial challenges of being on long-term, high-cost medications DOI Creative Commons

Cleopatra Elshiekh,

Roberta Rudà, Edward R. Scheffer Cliff

et al.

Neuro-Oncology Practice, Journal Year: 2024, Volume and Issue: 12(Supplement_1), P. i49 - i58

Published: Dec. 3, 2024

The isocitrate dehydrogenase (IDH) inhibitor, vorasidenib, may offer a promising new treatment option for patients with IDH-mutant gliomas. However, the indefinite nature of this targeted therapy raises significant financial concerns. High costs cancer therapies, often exceeding $150 000 annually, contribute to toxicity, characterized by medical debt, income loss, and psychological stress, place stress on health systems. This review analyzes drug approval pricing mechanisms in various countries their impact healthcare patient access, focusing specifically impacts neuro-oncology. United States employs market-driven approach resulting higher prices, while most countries, such as Kingdom, Germany, France, Italy, Japan, South Africa, Brazil, use negotiated technology assessment manage costs. burden expensive medications affects adherence quality life, many facing substantial out-of-pocket expenses potential abandonment, more unable access these drugs altogether. Vorasidenib's introduction, potentially improving outcomes, exacerbate toxicity unless mitigated programs cost-management strategies. As neuro-oncology paradigms evolve, understanding economic implications therapies is essential ensure equitable optimize care.

Language: Английский

Economic income and survival in patients affected by glioblastoma: A systematic review and meta-analysis DOI
Vincenzo Di Nunno, Lidia Gatto,

Marta Aprile

et al.

Neuro-Oncology Practice, Journal Year: 2024, Volume and Issue: 11(5), P. 546 - 555

Published: May 11, 2024

Within socioeconomic variables, economic income has been associated with the prognosis of patients glioblastoma. However, studies investigating this issue provided conflicting results.

Language: Английский

Citations

5
Brain metastases and mortality in patients with ALK + metastatic non-small cell lung cancer treated with second-generation ALK tyrosine kinase inhibitors as first-line targeted therapies: An observational cohort study DOI Creative Commons
Dipesh Uprety, Devin Abrahami, Zachary A. Marcum

et al.

Lung Cancer, Journal Year: 2025, Volume and Issue: 201, P. 108436 - 108436

Published: Feb. 4, 2025

Language: Английский

Citations

0
Epidemiology and Outcome of Primary Central Nervous System Tumors Treated at King Hussein Cancer Center DOI Open Access
Maysa Al‐Hussaini, Abdallah Al‐Ani, Justin Z. Amarin

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(4), P. 590 - 590

Published: Feb. 9, 2025

Primary central nervous system (CNS) tumors are often associated with relatively poor outcomes. Data on the epidemiology and outcome of CNS in Jordan scarce. We aim to report primary patients managed at a comprehensive cancer care center Jordan. performed retrospective chart review all Jordanian tumor diagnosis who were between July 2003 June 2019. included entities described 2021 WHO classification system, addition pituitary neuroendocrine (PitNETs). used Kaplan-Meier method estimate 1-year, 2-year, 5-year overall survival (OS) rates for each entity. 2094 cases. The numbers pediatrics adults 652 (31.1%) 1442 (68.9%), respectively. three most common groups "gliomas, glioneuronal tumors, neuronal tumors" (n = 1200 [57.30%]), followed by meningiomas 261 [12.5%]), embryonal 234 [11.2%]). families adult-type diffuse gliomas 709 [33.8%]), medulloblastoma 199 [9.5%]), circumscribed astrocytic 183 [8.7%]). median entire cohort was 97 months (95CI; 81-112). Survival significantly worse males compared their respective counterparts. Among group, tumors", OS lower than other types. Overall, adult IDH-mutations had advantage over wildtype cases (IDH-mutant 1-year OS, 89% [82-97%] vs. IDH-wildtype 60% [52-70%]; p < 0.001). present detailed analysis diagnosed largest these worldwide estimates found comparable trends.

Language: Английский

Citations

0
Defining interventions and metrics to improve diversity in CNS clinical trial participation: A SNO and RANO effort DOI Open Access
Joshua Budhu, Ugonma Chukwueke, Sadhana Jackson

et al.

Neuro-Oncology, Journal Year: 2023, Volume and Issue: 26(4), P. 596 - 608

Published: Dec. 10, 2023

Abstract Despite major strides in cancer research and therapy, these advances have not been equitable across race ethnicity. Historically marginalized groups (HMG) are more likely to inadequate preventive screening, increased delays diagnosis, poor representation clinical trials. Notably, Black, Hispanic, Indigenous people represent 30% of the population but only 9% oncology trial participants. As a result, HMGs lack access novel therapies, contradicting principle distributive justice, as enshrined Belmont report, which demands selection subjects involving human subjects. The diversity also leads low generalizability potentially harmful medical practices. Specifically, patients with brain face unique barriers enrollment completion due disease-specific neurologic treatment-induced conditions. Collectively, intersection conditions social determinants health fosters To ameliorate this disparity neuro-oncology participation, we present interventions focused on improving engagement HMGs. Proposals range from inclusive design, decreasing care, expanding eligibility, tumor profiling for personalized trials, setting reasonable metrics goals accrual, working patient community stakeholders, diversifying workforce, development tools overcome biases options incentivize equity. diversification participation amongst trials is imperative. Equitable inclusion HMG tumors will enhance discoveries improve care.

Language: Английский

Citations

8
Enhancing neuro-oncology care through equity-driven applications of artificial intelligence DOI

Mulki Mehari,

Youssef Sibih,

Abraham Dada

et al.

Neuro-Oncology, Journal Year: 2024, Volume and Issue: 26(11), P. 1951 - 1963

Published: Aug. 19, 2024

Abstract The disease course and clinical outcome for brain tumor patients depend not only on the molecular histological features of but also patient’s demographics social determinants health. While current investigations in neuro-oncology have broadly utilized artificial intelligence (AI) to enrich diagnosis more accurately predict treatment response, postoperative complications, survival, equity-driven applications AI been limited. However, advance health equity broader medical field potential serve as practical blueprints address known disparities neuro-oncologic care. In this consensus review, we will describe neuro-oncology, postulate viable solutions most pressing inequities based literature, propose a framework effective integration into AI-based research, close with limitations AI.

Language: Английский

Citations

2
Neuro-oncologic Emergencies DOI

Carolina B. Maciel,

Katharina M. Busl

CONTINUUM Lifelong Learning in Neurology, Journal Year: 2024, Volume and Issue: 30(3), P. 845 - 877

Published: June 1, 2024

Neuro-oncologic emergencies have become more frequent as cancer remains one of the leading causes death in United States, second only to heart disease. This article highlights key aspects epidemiology, diagnosis, and management acute neurologic complications primary central nervous system malignancies systemic cancer, following three thematic classifications: (1) that are anatomically or intrinsically tumor-related, (2) tumor-mediated, (3) treatment-related.

Language: Английский

Citations

0
Racial/ethnic disparities in all-cause and cause-specific death among children with malignant central nervous system tumours: a registry-based cohort retrospective analysis DOI Creative Commons
Hongying Wang, Bing Yao, Tao Tang

et al.

EClinicalMedicine, Journal Year: 2024, Volume and Issue: 76, P. 102816 - 102816

Published: Sept. 5, 2024

Language: Английский

Citations

0
Financial challenges of being on long-term, high-cost medications DOI Creative Commons

Cleopatra Elshiekh,

Roberta Rudà, Edward R. Scheffer Cliff

et al.

Neuro-Oncology Practice, Journal Year: 2024, Volume and Issue: 12(Supplement_1), P. i49 - i58

Published: Dec. 3, 2024

The isocitrate dehydrogenase (IDH) inhibitor, vorasidenib, may offer a promising new treatment option for patients with IDH-mutant gliomas. However, the indefinite nature of this targeted therapy raises significant financial concerns. High costs cancer therapies, often exceeding $150 000 annually, contribute to toxicity, characterized by medical debt, income loss, and psychological stress, place stress on health systems. This review analyzes drug approval pricing mechanisms in various countries their impact healthcare patient access, focusing specifically impacts neuro-oncology. United States employs market-driven approach resulting higher prices, while most countries, such as Kingdom, Germany, France, Italy, Japan, South Africa, Brazil, use negotiated technology assessment manage costs. burden expensive medications affects adherence quality life, many facing substantial out-of-pocket expenses potential abandonment, more unable access these drugs altogether. Vorasidenib's introduction, potentially improving outcomes, exacerbate toxicity unless mitigated programs cost-management strategies. As neuro-oncology paradigms evolve, understanding economic implications therapies is essential ensure equitable optimize care.

Language: Английский

Citations

0